Shenox receives allowances for...

Shenox is pleased to announce that allowances for the first patent for a transdermal delivery system for ketamine have been received from multiple countries including Japan, South Korean, Australia, C

Progress of SHX-001

Shenox completed a phase 2b preparation meeting with the FDA and has reached agreements on nonclinical requirements and overall clinical design.

SHX-001 completed the first pa...

On January 21, 2019, Shenox completed the administration of first MDD patient in the SHX-001 First in Human trial at the Maryland site in US.